New PGRN Featured Project and PI for the Month of July
The PGRN website is featuring a new project and investigator of the month from the PHAT (Pharmacogenetics of Asthma Treatment) group.
For detailed information, please visit the PGRN website.
More issues
Effect of a genetic variant associated with Multiple Sclerosis mirrors response to anti-TNF therapy
Though anti-TNF therapy can be effective in the treatment of many auto-immune diseases including Rheumatoid Arthritis (RA), drugs that block TNF can promote or exacerbate Multiple Sclerosis (MS).
A genetic variant (rs1800693) within the TNFRSF1A gene has been identified in multiple GWAS as being associated with MS but not associated
New pathways on PharmGKB: Sorafenib PK and PD
We have added two new pathways: Sorafenib PK and PD pathways to our pathway collections.
Sorafenib (Nexavar, BAY 43-9006) is a cancer drug used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma. It blocks tumor cell proliferation and angiogenesis by targeting various types of serine/threonine and receptor
New Relationships File Available
PharmGKB has a new relationships file available for download. This file catalogs all the current relationships between drugs, genes, diseases, variants, and haplotypes in PharmGKB. These relationships are based on annotations generated by our curators.
The new relationships file replaces and improves on the old relationships file. The entries in
PharmGKB has an opening for a scientific curator
PharmGKB is looking to fill a Curator position in the Department of Genetics at Stanford University. We are specifically looking for someone with a clinical or pharmacology background to add to the curation team.
This position works with a group of curators to collect and analyze information from the scientific
Genetic contribution of response to opioids
Opioids are commonly prescribed for pain relief, yet many individuals suffer adverse side effects such as nausea, dizziness and sedation.
A study published in this month's Anesthesiology set out to establish the relative contribution of genetic and environmental factors in opioid response. 114 monozygotic and dizygotic twin pairs
Helix Group & PharmGKB Retreat
Much fun and team-building was had at the Stanford Helix Group & PharmGKB retreat in San Diego last week - including sea kayaking, insightful talks and a lively discussion with guest speaker Philip Bourne.
Curators' Favorite Papers
The current Curators' Favorite Papers are about pharmacogenomics of antidepressant drugs. Narasimhan and Lohoff review recent findings on the pharmacogenetics of antidepressant drugs and discuss possible future clinical implementations [PMID: 22380000]. The study by de Klerk et al. investigates the association of ABCB1 variants with adverse effects of antidepressants
Metformin Pharmacogenomics
Metformin is a first line therapy for type 2 diabetes, and is one of the most commonly prescribed drugs worldwide. We have recently written a Metformin Pathways Summary that is published in Journal Pharmacogenetics and Genomics.
Metformin effectively lowers both basal and postprandial plasma glucose. However, the glycemic response to
New haplotypes available on PharmGKB
Haplotypes for the UGT1A3, CYP2F1 and CHRNA5 genes are now available on www.pharmgkb.org
View a list of all the genes with haplotypes available on PharmGKB.